Review Article

High Blood Pressure & Cardiovascular Prevention

, Volume 22, Issue 2, pp 99-102

Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?

  • Chiara LonatiAffiliated withDivision of Internal Medicine and Hypertension Center, Department of Clinical Sciences and Community Health, San Giuseppe Hospital, University of MilanDepartment of Internal Medicine, Ospedale San Giuseppe Email author 
  • , Alberto MorgantiAffiliated withDivision of Internal Medicine and Hypertension Center, Department of Clinical Sciences and Community Health, San Giuseppe Hospital, University of Milan

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The antagonists of the renin–angiotensin system (RAS) have gained increasing popularity in the last two decades due to their indisputable efficacy in a number of cardiovascular disorders, coupled with an unsurpassed tolerability. However some years ago a partial and non-predefined meta-analysis raised the possibility that angiotensin receptor antagonists in particular may increase the incidence of cancer. This observation, although not confirmed by subsequent, larger analyses, caused a remarkable and understandable concern even outside the medical community. Herein we will summarize the available evidence pro and con the hypothesis of a carcinogenetic activity of RAS antagonists coming to the conclusion that these drugs may actually exert an anticancer action.

Keywords

Renin-angiotensin system Renin-angiotensin system antagonists Cancer